Gilead Sciences Inc
(NAS:GILD)
$
88.08
-0.68 (-0.77%)
Market Cap: 109.66 Bil
Enterprise Value: 131.08 Bil
PE Ratio: 107.41
PB Ratio: 6.00
GF Score: 79/100 Gilead Sciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 03:30PM GMT
Release Date Price:
$76.8
(-0.31%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Thanks so much for joining us, everybody. Really pleased to be here hosting Gilead. Before we get started, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley, and we're very pleased to have Dan O'Day with us. Dan is Chairman and CEO; and Andy Dickinson, who is the company's CFO. But thank you both for taking time out of your day to join us today.
Daniel P. O;Day
Gilead Sciences, Inc. - Chairman & CEO
' -
Pleasure.
Questions & Answers
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
I thought maybe we'd start off high level. Obviously, diversification has been a key part of the Gilead story and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot